Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Apr. 19];4(5):s68. Available from: https://skin.dermsquared.com/skin/article/view/1017